Recent submissions
Now showing items 221-240 of 4698
-
Effect of Metformin Versus Placebo on New Primary Cancers in Canadian Cancer Trials Group MA.32: A Secondary Analysis of a Phase III Randomized Double-Blind Trial in Early Breast Cancer.
(LIPPINCOTT WILLIAMS & WILKINS, 2023-12-10)Clinical trials frequently include multiple end points that mature at different times. The initial report, typically based on the primary end point, may be published when key planned coprimary or secondary analyses are not ... -
ESMO Guidance for Reporting Oncology real-World evidence (GROW).
(ELSEVIER, 2023-10-15) -
Clinical practice guidelines for the diagnosis and surveillance of BAP1 tumour predisposition syndrome.
(SPRINGERNATURE, 2023-11-01)BRCA1-associated protein-1 (BAP1) is a recognised tumour suppressor gene. Germline BAP1 pathogenic/likely pathogenic variants are associated with predisposition to multiple tumours, including uveal melanoma, malignant ... -
Lysine-targeting covalent inhibitors
(Institute of Cancer Research (University Of London), 2023-12-14)Targeted Covalent Inhibitors (TCIs) represent an increasingly important strategy in modern drug discovery. TCIs exploit high affinity, reversible ligands which are then modified with modestly-reactive electrophilic warheads ... -
Deconstructing the soft tissue sarcoma matrisome and adhesome for drug target and biomarker discovery
(Institute of Cancer Research (University Of London), 2023-12-08)Soft tissue sarcomas (STS) are a rare and diverse group of mesenchymal malignancies that present significant challenges in clinical management due to their extensive clinical and biological heterogeneity. STS have a dismal ... -
Unravelling the mechanisms of acquired immunomodulatory drug resistance in multiple myeloma
(Institute of Cancer Research (University Of London), 2023-12-01)Immunomodulatory drugs (IMiDs) are a cornerstone of multiple myeloma treatment and newer cereblon E3 ligase modulating drugs (CELMoDs) are in clinical trials. However, a major barrier to improving patient outcomes is ... -
Homologous recombination deficiency in newly diagnosed FIGO stage III/IV high-grade epithelial ovarian cancer: a multi-national observational study.
(BMJ PUBLISHING GROUP, 2023-08-07)OBJECTIVE: Olaparib plus bevacizumab maintenance therapy improves survival outcomes in women with newly diagnosed, advanced, high-grade ovarian cancer with a deficiency in homologous recombination. We report data from the ... -
Intracellular antibodies and biodegraders: Beyond small molecules and back again
(ELSEVIER, 2023-09-01) -
Defining novel immune biomarkers of prognosis and immunotherapy sensitivity in gastro-oesophageal and colorectal cancers
(Institute of Cancer Research (University Of London), 2023-11-28)Background Gastro-oesophageal adenocarcinomas (GOAs) frequently recur after resection; prognostic and predictive markers are absent. Mismatch repair-deficient (MMRd) GOAs have high mutational burden, are frequently ... -
Low-grade serous ovarian cancer: expert consensus report on the state of the science.
(BMJ PUBLISHING GROUP, 2023-09-04)Compared with high-grade serous carcinoma, low-grade serous carcinoma of the ovary or peritoneum is a less frequent epithelial ovarian cancer type that is poorly sensitive to chemotherapy and affects younger women, many ... -
Repeatability of quantitative individual lesion and total disease multiparametric whole-body MRI measurements in prostate cancer bone metastases.
(BRITISH INST RADIOLOGY, 2023-11-01)OBJECTIVES: To assess the repeatability of quantitative multiparametric whole-body MRI (mpWB-MRI) parameters in advanced prostate cancer (APC) bone metastases. METHODS: 1.5T MRI was performed twice on the same day in 10 ... -
Results of the SEL-I-METRY Phase II Trial on Resensitization of Advanced Iodine Refractory Differentiated Thyroid Cancer to Radioiodine Therapy.
(MARY ANN LIEBERT, INC, 2023-09-01) -
Surgical Inflammation Alters Immune Response to Intraoperative Photodynamic Therapy.
(AMER ASSOC CANCER RESEARCH, 2023-09-11)UNLABELLED: Surgical cytoreduction for patients with malignant pleural mesothelioma (MPM) is used for selected patients as a part of multi-modality management strategy. Our group has previously described the clinical use ... -
Hitting the Target: Developing High-quality Evidence for Proton Beam Therapy Through Randomised Controlled Trials.
(ELSEVIER SCIENCE LONDON, 2023-11-08)The National Health Service strategy for the delivery of proton beam therapy (PBT) in the UK provides a unique opportunity to deliver high-quality evidence for PBT through randomised controlled trials (RCTs). We present a ... -
Quest markup for developing FAIR questionnaire modules for epidemiologic studies.
(BMC, 2023-10-25)BACKGROUND: Online questionnaires are commonly used to collect information from participants in epidemiological studies. This requires building questionnaires using machine-readable formats that can be delivered to study ... -
Dabrafenib plus trametinib versus anti-PD-1 monotherapy as adjuvant therapy in BRAF V600-mutant stage III melanoma after definitive surgery: a multicenter, retrospective cohort study.
(ELSEVIER, 2023-11-01)BACKGROUND: Both dabrafenib/trametinib (D/T) and anti-PD-1 monotherapy (PD-1) are approved adjuvant therapies for patients with stage III BRAF V600-mutant melanoma. However, there is still a lack of head-to-head comparative ... -
Androgen receptor binding sites enabling genetic prediction of mortality due to prostate cancer in cancer-free subjects.
(NATURE PORTFOLIO, 2023-08-23)Prostate cancer (PrCa) is the second most common cancer worldwide in males. While strongly warranted, the prediction of mortality risk due to PrCa, especially before its development, is challenging. Here, we address this ... -
ESR1 F404 Mutations and Acquired Resistance to Fulvestrant in ESR1-Mutant Breast Cancer.
(AMER ASSOC CANCER RESEARCH, 2024-02-08)UNLABELLED: Fulvestrant is used to treat patients with hormone receptor-positive advanced breast cancer, but acquired resistance is poorly understood. PlasmaMATCH Cohort A (NCT03182634) investigated the activity of fulvestrant ... -
Ten-Year Outcomes of Stereotactic Body Radiotherapy for Oligometastatic Breast Cancer: Does Synchronous Oligometastatic Breast Cancer Benefit?
(ELSEVIER SCIENCE LONDON, 2023-11-01)AIMS: The benefit of stereotactic body radiotherapy (SBRT) in metachronous oligometastatic breast cancer (OMBC) has previously been described and its use in current clinical practice is established. The role of SBRT in the ... -
Bempegaldesleukin Plus Nivolumab in Untreated Advanced Melanoma: The Open-Label, Phase III PIVOT IO 001 Trial Results.
(LIPPINCOTT WILLIAMS & WILKINS, 2023-10-20)PURPOSE: Despite marked advances in the treatment of unresectable or metastatic melanoma, the need for novel therapies remains. Bempegaldesleukin (BEMPEG), a pegylated interleukin-2 (IL-2) cytokine prodrug, demonstrated ...